Epoch Investment Partners Inc. Decreases Holdings in Medtronic PLC $MDT

Posted by George Bondi on Jul 25th, 2026

Epoch Investment Partners Inc. reduced its position in Medtronic PLC (NYSE:MDT – Free Report) by 1.5% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 855,500 shares of the medical technology company’s stock after selling 13,410 shares during the period. Epoch Investment Partners Inc.’s holdings in Medtronic were worth $74,129,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Entropy Technologies LP purchased a new stake in shares of Medtronic in the first quarter valued at about $17,640,000. TCM Advisors LLC raised its position in shares of Medtronic by 6.7% during the 1st quarter. TCM Advisors LLC now owns 11,218 shares of the medical technology company’s stock worth $972,000 after purchasing an additional 700 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund lifted its stake in Medtronic by 4.2% in the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 530,048 shares of the medical technology company’s stock valued at $45,929,000 after buying an additional 21,344 shares in the last quarter. Morningstar Investment Management LLC grew its holdings in Medtronic by 10.3% during the 1st quarter. Morningstar Investment Management LLC now owns 48,878 shares of the medical technology company’s stock valued at $4,235,000 after buying an additional 4,556 shares during the last quarter. Finally, GC Wealth Management RIA LLC grew its holdings in Medtronic by 1.3% during the 1st quarter. GC Wealth Management RIA LLC now owns 42,988 shares of the medical technology company’s stock valued at $3,725,000 after buying an additional 562 shares during the last quarter. 82.06% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Medtronic

In other news, EVP Harry Skip Kiil sold 4,189 shares of the business’s stock in a transaction on Monday, June 8th. The shares were sold at an average price of $80.44, for a total transaction of $336,963.16. Following the completion of the sale, the executive vice president directly owned 37,227 shares of the company’s stock, valued at $2,994,539.88. The trade was a 10.11% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.26% of the stock is currently owned by company insiders.

Medtronic Stock Up 1.4%

MDT opened at $83.12 on Friday. Medtronic PLC has a 12 month low of $73.31 and a 12 month high of $106.33. The business has a 50-day moving average of $80.15 and a two-hundred day moving average of $87.52. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.13 and a quick ratio of 1.62. The stock has a market capitalization of $106.40 billion, a price-to-earnings ratio of 22.28, a price-to-earnings-growth ratio of 2.20 and a beta of 0.56.

Medtronic (NYSE:MDT – Get Free Report) last announced its quarterly earnings data on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.01. Medtronic had a net margin of 13.20% and a return on equity of 14.51%. The business had revenue of $9.81 billion for the quarter, compared to analyst estimates of $9.62 billion. During the same period in the prior year, the firm posted $1.62 EPS. The company’s revenue was up 9.9% on a year-over-year basis. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. On average, research analysts expect that Medtronic PLC will post 5.94 earnings per share for the current year.

Medtronic Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, July 17th. Shareholders of record on Friday, June 26th were paid a dividend of $0.72 per share. This is an increase from Medtronic’s previous quarterly dividend of $0.71. This represents a $2.88 dividend on an annualized basis and a yield of 3.5%. The ex-dividend date of this dividend was Friday, June 26th. Medtronic’s payout ratio is 77.21%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on MDT shares. Rothschild & Co Redburn cut their price target on Medtronic from $111.00 to $106.00 and set a “buy” rating for the company in a report on Friday, June 5th. Jefferies Financial Group reissued a “hold” rating and issued a $88.00 target price on shares of Medtronic in a research note on Thursday, June 4th. UBS Group reduced their target price on shares of Medtronic from $90.00 to $85.00 and set a “neutral” rating on the stock in a report on Thursday, June 4th. The Goldman Sachs Group decreased their price target on shares of Medtronic from $84.00 to $83.00 and set a “neutral” rating on the stock in a research note on Thursday, June 4th. Finally, Stifel Nicolaus set a $80.00 price target on shares of Medtronic in a report on Wednesday, June 3rd. Seventeen equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $98.21.

Read Our Latest Research Report on Medtronic

About Medtronic

(Free Report)

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).